Pharmacist-Led Continuous Glucose Monitoring for Prediabetes

This observational study is looking at whether a program led by a pharmacist, using a continuous glucose monitor (CGM) called Dexcom Stelo, can help people with prediabetes better control their blood sugar and make healthier choices. The Dexcom Stelo is a small device worn on your upper arm that tracks your glucose levels. Researchers want to see if using this device with pharmacist guidance improves your A1c (a measure of average blood sugar over 2-3 months) after 12 weeks. You might be able to join if you are 18-70 years old, have prediabetes (A1c between 5.7-6.4%), and have a compatible smartphone. You also can't have worn a CGM in the last 6 months. The study is currently unclear about its recruitment status.

Study design: This is an observational study with a planned enrollment of 40 participants. It compares participants using the Dexcom Stelo CGM with a pharmacist-led program to a group of past patients who did not use a CGM.
What's involved: If you join, you will wear Dexcom Stelo CGM sensors on your upper arm for 12 weeks, changing them every 15 days.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint measures changes in A1c at the end of the 12-week study period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Pharmacist-Led Continuous Glucose Monitoring for Prediabetes

Recruiting

Not specifiedAges 18–70Observational

University of South Florida

~40 participants

Updated 2026-08-10 on ClinicalTrials.gov

What's tested:Dexcom Stelo CGM

At a glance

Recruiting sites

2 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change in hemoglobin A1c

Measured over Baseline to End of Study (12 weeks)

Conditions

Prediabetes

Where it's being run

2 sites across 1 states

Florida2

Study leadership

Kevin Cowart, PharmD, MPH · PRINCIPAL_INVESTIGATOR · University of South Florida

Who to contact

Kevin Cowart, PharmD, MPH

[email protected]

813-974-5562

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

adults 18-70 years of age

prediabetes (HbA1c 5.7-6.4%)

compatible smartphone with the Dexcom Stelo sensor system

have not have worn a CGM in the last 6 months prior to enrollment

Exclusion

any of the following forms of diabetes: type 1 diabetes, type 2 diabetes, monogenic diabetes, cystic fibrosis-related diabetes, post- transplant diabetes, latent autoimmune diabetes

problematic hypoglycemia in the prior 6 months \[defined as recurrent (more than one) level 2 hypoglycemic events (glucose \<54mg/dL ) that persist despite multiple attempts to adjust medication(s) and/or modify the diabetes/treatment plan or a history of one level 3 hypoglycemic event (glucose \<54mg/dL) characterized by altered mental and/or physical state requiring third-party assistance for treatment of hypoglycemia\]

pregnant, or planning to become pregnant during the study time frame

currently receiving or planned to receive dialysis during the study time frame - current use of systemic steroids for any condition

a known allergy to medical grade adhesives,

use of any CGM device in the past 6 months

history of a diagnosed eating disorder

current use of a second-generation antipsychotic at the time of consent (aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)

subjects lacking capacity to provide informed consent

What this trial measures

Change in hemoglobin A1cBaseline to End of Study (12 weeks)
Between-group difference in change in hemoglobin A1c at 12 weeks, %, compared between intervention and historical cohort

Trialytics